8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Japanese drug major Eisai’s shares closed up 6% at 12.075 yen today, as it revealed an exclusive global agreement with the USA’s Bristol Myers Squibb for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC), that could earn the company more than $3 billion. 18 June 2021
Dutch specialty pharma company Pharming Group said today it has appointed Anurag Relan as chief medical officer (CMO), effective immediately, and Robert Friesen as chief scientific officer, effective from August 1, 2021. 18 June 2021
US science and technology conglomerate Danaher Corporation has entered into a definitive agreement to acquire privately-held biotech firm Aldevron, a fast-growing producer of plasmid DNA, mRNA and recombinant proteins that are used for vaccines, including those for the current coronavirus pandemic. 18 June 2021
FibroGen and fellow USA-based HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, have announced a partnership covering three HiFiBiO programs. 18 June 2021
Charnwood Molecular, a UK-based pre-clinical discovery contract research organization (CRO) has announced the acquisition of the assay development and biological screening provider, Aurelia Bioscience. 18 June 2021
Gilead Sciences’ subsidiary has announced a strategic partnership with privately held US biotech Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets. 18 June 2021
Swiss pharma major Novartis has secured a positive reimbursement decision in the UK for Cosentyx (secukinumab) as an option for certain people with active non-radiographic axial spondyloarthritis. 17 June 2021
The Russia Ministry of Health of the Russian Federation has approved pathogenetic therapy of cytokine release syndrome in patients with moderate to severe new coronavirus infection (COVID-19) as an additional indication to be included in the olokizumab SmPC. 17 June 2021
Positive findings from the STOP-COVID study (NCT04469114) evaluating the efficacy and safety of oral Janus kinase (JAK) inhibitor tofacitinib in 289 hospitalized adult patients with COVID-19 pneumonia who were not on ventilation have been published in that the New England Journal of Medicine. 17 June 2021
The US government has purchased an additional 200 million doses of the coronavirus vaccine developed by Moderna, in case boosters are needed. 17 June 2021
In an environment with continued pricing pressure biopharma executives are asking themselves: Can we discover and develop new medicines that improve patient outcomes whilst solving access challenges? 17 June 2021
Having scored a historic first last week, with accelerated US regulatory approval for the use of its Aduhelm (aducanumab) as the first treatment in nearly two decades to address an underlying cause of Alzheimer's disease, yesterday US biotech major Biogen (Nasdaq: BIIB) also added to the list of failures in the search for such treatments. 17 June 2021
The US Food and Drug Administration approved Cambridge, Massachusetts-based Blueprint Medicines’ Ayvakit (avapritinib) for adult patients with advanced systemic mastocytosis (AdvSM). 17 June 2021
German vaccines developer CureVac saw its shares halve in value overnight, after the firm announced its coronavirus vaccine had failed late-stage testing. 17 June 2021
US biotech Regeneron Pharmaceuticals’ shares were up 2.4% at $40.16 in early trading today, as new results of a large UK clinical trial showed the company’s antibody cocktail improved survival in hospitalized COVID-19 patients. 16 June 2021
In a second cardiometabolic deal signed this month, Danish diabetes care giant Novo Nordisk has now entered into a collaboration with privately-held US biotech Lumen Bioscience. 16 June 2021
Japanese pharma major Daiichi Sankyo has pulled the plug on development of an inhaled formulation of nafamostat, dubbed DS-2319, as a treatment for COVID-19. 16 June 2021
Vyepti (eptinezumab-jjmr) met both co-primary endpoints of the RELIEF study, published today in the Journal of the American Medical Association (JAMA), showing early benefit for time to headache pain freedom, and time to the absence of most bothersome symptoms (MBS), compared to placebo, said Danish CNS specialist Lundbeck. 16 June 2021
Swiss-American biotech CRISPR Therapeutics and USA-based Capsida Biotherapeutics have entered into a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. 15 June 2021
Biogen’s near-billion dollar bet on Nightstar Therapeutics looks set to lose spectacularly, following the failure of the Phase III STAR study of lead candidate timrepigene emparvovec. 15 June 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.